Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Must Adopt Innovative Drugs & AI ‘At Scale’ To Plug Cancer Care Gaps

Executive Summary

European countries should establish “implementation budgets” to fund innovative cancer therapies and leverage technologies such as AI in drug R&D to meet the rising demand for cancer care, pharmaceutical industry representatives say.

You may also be interested in...



Pharma Industry Urges HTA Bodies To Look Beyond Survival Data For Cancer Drugs

A new report by industry association EFPIA says that health technology assessment bodies often rely too heavily on overall survival data when assessing the value of novel cancer drugs, and should take into account other clinical and patient-reported outcome measures where appropriate.

EMA Opens Discussion On Appropriate Use Of AI In Drug Lifecycle

The European Medicines Agency is inviting feedback on a draft reflection paper that outlines the scientific principles companies should follow when using AI tools in the medicinal product lifecycle.

EU Countries Focus On National Best Practices For Decentralized Trial Approvals & Inspections

The EU recommendation paper on decentralized clinical trials (DCTs) marked an important “first step” on the direction the European regulatory network wants to take with DCTs. Member states are now focused on reviewing and tracking DCTs to gain experience before considering the need for any updates to the recommendation paper. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel